Nanobiotix’s NBTXR3 meets in Phase II/III for STS

Nanobiotix S.A. (Euronext:NANO) said NBTXR3 met the primary and secondary endpoints in the Phase II/III act.in.sarc trial to treat locally advanced soft

Read the full 225 word article

User Sign In